CliffBio
small molecule

DIACOMIT

STIRIPENTOL

Loss of exclusivityJuly 2029FDA regulatory exclusivity expiry
CompanyBiocodex →View the full company profile on CliffBio

Drug detail

Brand nameDIACOMIT
Active ingredientSTIRIPENTOL
Strength500MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2018
Marketing statusRX

Regulatory exclusivity

CodeExpires
ODE-403July 2029

More from Biocodex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

DIACOMIT patent cliff — loss of exclusivity July 2029 | CliffBio